RxDoctor Payments Data

Sasan Raissi, MD

Cardiovascular Disease · Chicago, ILNPI 1346537826

Payments from drug & device makers

$68,169in general payments, 2019–2025

Across 208 payments — averaging $327.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$50K
  • Edwards Lifesciences$7K
  • Philips North America LLC$6K
  • Ancora Heart, Inc.$1K
  • Heartflow, Inc.$1K
  • Boston Scientific$1K
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$43,21063%
  • Speaking & faculty fees$9,37814%
  • Travel & lodging$7,58111%
  • Food & beverage$8,00112%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,169 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$320,747
Medicare patients
1,833
Services billed
5,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$198,250
EntrestoSacubitril/Valsartan74$105,228
JardianceEmpagliflozin75$94,210
FarxigaDapagliflozin Propanediol49$59,564
Repatha SureclickEvolocumab56$45,528
XareltoRivaroxaban19$27,028
BrilintaTicagrelor11$6,440
Ranolazine ErRanolazine53$5,891
Irbesartan249$5,536
Metoprolol Succinate384$5,088
Atorvastatin Calcium257$3,556
Carvedilol369$3,371
Pravastatin Sodium167$3,334
Felodipine ErFelodipine120$3,284
Rosuvastatin Calcium115$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$198,250210 claims
NovartisEntresto$109$105,22874 claims
Boehringer IngelheimJardiance$158$94,21075 claims
AstraZenecaFarxiga, Brilinta$81$66,00460 claims
Johnson & JohnsonXarelto$111$27,02819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →